Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-08 5:24 pm Unchanged |
2023-02-08 | 13G | Terns Pharmaceuticals, Inc. TERN |
BML Investment Partners, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-08 5:23 pm Sale |
2023-02-08 | 13G | Terns Pharmaceuticals, Inc. TERN |
BML Investment Partners, L.P. | 0 0.000% |
-1,764,274 (Position Closed) |
Filing History |
| 2023-02-06 2:45 pm Sale |
2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 2,901,566 6.100% |
-63,304 (-2.14%) |
Filing History |
| 2023-01-03 4:58 pm Purchase |
2022-12-21 | 13G | Terns Pharmaceuticals, Inc. TERN |
SUVRETTA CAPITAL MANAGEMENT, LLC | 3,448,275 7.000% |
3,448,275 (New Position) |
Filing History |
| 2022-12-29 2:57 pm Sale |
2022-12-27 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 2,964,870 6.180% |
-1,816,696 (-37.99%) |
Filing History |
| 2022-12-28 5:14 pm Purchase |
2022-12-23 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,619,135 15.400% |
137,931 (+1.84%) |
Filing History |
| 2022-12-23 3:35 pm Purchase |
2022-12-23 | 13G | Terns Pharmaceuticals, Inc. TERN |
Flynn James E | 2,851,287 5.940% |
991,287 (+53.30%) |
Filing History |
| 2022-12-12 08:41 am Purchase |
2022-12-09 | 13G | Terns Pharmaceuticals, Inc. TERN |
FMR CORP | 5,642,074 14.999% |
5,539,780 (+5415.55%) |
Filing History |
| 2022-08-26 7:24 pm Purchase |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 3,066,241 8.200% |
3,066,241 (New Position) |
Filing History |
| 2022-08-25 09:32 am Purchase |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Fairmount Funds Management LLC | 2,050,000 5.450% |
2,050,000 (New Position) |
Filing History |
| 2022-08-18 4:39 pm Purchase |
2022-08-16 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,481,204 19.900% |
3,690,000 (+97.33%) |
Filing History |
| 2022-08-16 5:20 pm Sale |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Flynn James E | 1,860,000 4.940% |
-485,959 (-20.71%) |
Filing History |
| 2022-06-10 11:04 am Sale |
2022-06-09 | 13G | Terns Pharmaceuticals, Inc. TERN |
FMR CORP | 102,294 0.404% |
-2,698,691 (-96.35%) |
Filing History |
| 2022-06-07 4:41 pm Purchase |
2022-06-01 | 13G | Terns Pharmaceuticals, Inc. TERN |
BML Investment Partners, L.P. | 1,764,274 7.000% |
1,764,274 (New Position) |
Filing History |
| 2022-04-06 10:27 am Purchase |
2022-04-06 | 13G | Terns Pharmaceuticals, Inc. TERN |
Auspice Ltd | 1,411,206 5.600% |
1,411,206 (New Position) |
Filing History |
| 2022-02-11 4:15 pm Sale |
2021-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Flynn James E | 2,345,959 9.280% |
-36,074 (-1.51%) |
Filing History |
| 2022-02-09 12:29 pm Purchase |
2021-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 4,781,566 18.900% |
4,781,566 (New Position) |
Filing History |
| 2022-02-09 10:01 am Sale |
2022-02-08 | 13G | Terns Pharmaceuticals, Inc. TERN |
FMR CORP | 2,800,985 11.085% |
-86,753 (-3.00%) |
Filing History |
| 2021-04-12 1:05 pm Purchase |
2021-04-09 | 13G | Terns Pharmaceuticals, Inc. TERN |
FMR CORP | 2,887,738 11.493% |
2,887,738 (New Position) |
Filing History |
| 2021-02-22 6:31 pm Purchase |
2021-02-09 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 3,791,204 15.100% |
3,791,204 (New Position) |
Filing History |